Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain?

Bruker Corporation BRKR has introduced an innovative Fourier 80 multinuclear benchtop FT-Nuclear Magnetic Resonance (NMR) spectrometer, known as the ‘Multi-Talent’ configuration. Unveiled at the Joint ENC-ISMAR Conference 2025, the system’s unique, next-generation capabilities meet the evolving needs of academic researchers and industry scientists with significantly enhanced versatility in benchtop FT-NMR multinuclear analysis.

The latest development from Bruker marks a major advancement in permanent magnet-based FT-NMR technology and is expected to boost the performance of its BioSpin Group.

BRKR Stock’s Likely Trend Following the News

Since the announcement on April 7, Bruker shares have dropped 1.6%, closing at $38.07 in yesterday’s session. On a promising note, the company already has successfully installed a dozen Fourier 80 multinuclear systems in customer labs, and expects that the latest Fourier 80 multinuclear benchtop FT-NMR system may become the new de facto standard in benchtop multinuclear NMR spectroscopy. Accordingly, we anticipate this to boost the market sentiment toward BRKR stock.

Bruker has a market capitalization of $6.25 billion. The Zacks Consensus Estimate for the company’s 2025 earnings per share (EPS) indicates an increase of 11.6%. In the trailing four quarters, it delivered an earnings beat of 3.7%, on average.

Significance of Bruker’s New Benchtop FT-NMR

The Fourier 80 ‘Multi-Talent’ system measures or decouples1H, and in addition, can select one of 15 different X-nuclei to be either observed in X{1H} experiments or selected X-nuclei can be decoupled for proton observation in 1H{X} experiments. This enables many types of X-nucleus observations, various 2D experiments and also the exquisitely sensitive inverse 1H observation methods for 13C, 19F or 15N experiments.

Similarly, the Fourier 80 ‘Multi-Talent’ can observe 19F{1H} with proton decoupling for the simplification of 19F spectra, a capability of high interest to pharmaceutical customers studying fluorinated drug candidates. For battery research, the Fourier 80 ‘Multi-Talent’ enables nuclei observations from Li-brine mining, like 7Li, 23Na and 11B for the formulation of battery electrolytes. Novel electrochemical systems can be explored to advance next-generation battery technologies. These unprecedented benchtop capabilities are selectable via software, eliminating the need for NMR probe tuning and matching.

The ‘Multi-Talent’ uses standard 5 mm NMR samples and includes gradient spectroscopy with options for adjustable sample temperature or sample changer automation. The user-friendly Fourier 80 interface ensures that novice and experienced users can navigate through measurements effortlessly, streamlining complex tasks and enhancing productivity.

Bruker’s Industry Prospects Favorable

Per a research report, the benchtop NMR spectrometer market was valued at $350 million in 2024 and is expected to grow at a compound annual rate of 5.5% through 2033. More organizations are turning to NMR technology to improve their workflows and minimize waste, enhancing their overall efficiency. The trend has gained more traction with the increasing R&D activities, particularly in the pharmaceutical and biotechnology sectors.

Other Developments in Bruker

This month, Bruker announced the first customer installation of its groundbreaking dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer. The novel Polarizer enables scientists to conduct previously impossible experiments in chemical or metabolic analysis in NMR and preclinical MRI. Bruker provides a faster d-DNP approach using cross-polarization of 1H and 13C, which offers 5-10x faster polarization compared to traditional d-DNP of 13C.

BRKR Stock Price Performance

In the past three months, Bruker shares have declined 39.5% compared with the industry’s 35% fall.

BRKR’s Zacks Rank and Key Picks

Bruker currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space include Veracyte VCYT, Insulet PODD and Abbott ABT. Each of these carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Estimates for Veracyte’s 2025 EPS have jumped 6.9% in the past 30 days. Shares of the company have risen 49.5% in the past year against the industry’s 11.3% fall. Its earnings yield of 3.8% compares to the industry’s -3.6% yield. VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 515.9%.

Insulet shares have rallied 43.5% in the past year. The company has an estimated long-term earnings growth rate of 25.9% compared to the industry’s 16.5% growth. PODD’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 27.5%. In the last reported quarter, it posted an earnings surprise of 9.5%.

Estimates for Abbott’s 2025 EPS have remained constant at $5.15 in the past 30 days. Shares of the company have jumped 14.1% in the past year compared to the industry’s 1.5% growth. It has an earnings yield of 4.1% compared to the industry’s flat yield. ABT’s earnings surpassed estimates in three of the trailing four quarters and matched in one, the average surprise being 1.6%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research